All in all, the results are better than expected and convincing. |
All of the company's business segments have contributed strongly to the earnings improvement, which shows that the past years' efforts to improve efficiency have paid off. |
Bayer has now manifest its will to move forward. This is positive because now we know they can stick to their time frame. |
I think Engelhard is opening up to a friendly transaction. |
If the final price comes in over $40 per share, we would consider this negative. |
It's clearly BASF's strategic thinking not to give in and raise the price unless they get some information that justifies it. |
Strengthening their product range further down the value chain makes a lot of sense. |
The company's salt acquisitions are paying off big time thanks to the winter weather. |
The pain threshold is around $40. They can't go a lot over $40 without the capital markets seeing that negatively. There is a point where a price would not justify the transaction. |
The results were in line. The chemicals cycle is humming right now. The high dividend is not surprising, seeing the growth in profit. |
This is a good amendment of Bayer's cardiology and hematology portfolio. |
This is a good building block for Bayer. |
This is a real setback. |
This move comes as a surprise, but BASF so far has an excellent track record in acquisitions that were always adding value to investors. |